MeiraGTx Reports Second Quarter 2023 Financial and Operation

Phase 3 LUMEOS clinical trial of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) enrollment target has now been surpassedAnnounced positive clinical data from the completed AQUAx Phase 1 study of AAV2-hAQP1 for the treatment of grade 2/3 radiation-induced xerostomia (RIX), showing bilaterally treated participants reaching normal levels of whole saliva flow rate by 2 months post-treatment and persisting through the final Month 12

Related Keywords

Ireland , London , City Of , United Kingdom , United States , American , Jason Braco , Association For Research , Lifesci Communications , American Society Of Gene , Meiragtx Holdings , Nasdaq , Cell Therapy , Alexandria Forbes , Development Highlights , Anticipated Milestones , Induced Xerostomia , Owned Gene Therapy Manufacturing Facility , Received Commercial , Gene Regulation Platform , Vector Engineering , Private Securities Litigation Reform Act , Quarterly Report , Six Month Period Ended June , Meiragtx , Gene Regulation , Gene Therapy , Clinical Programs , Clinical Stage , Shannon , Clinical Trials ,